Parallax Volatility Advisers
EGRX

Parallax Volatility Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Parallax Volatility Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-22,500
Closed -$873K – 4135
2016
Q2 		$873K Buy
+22,500
New +$937K ﹤0.01% 1243
2015
Q4 		– Sell
-20,000
Closed -$1.48M – 4104
2015
Q3 		$1.48M Buy
+20,000
New +$1.66M ﹤0.01% 1145

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Parallax Volatility Advisers's EGRX Position: Q2 2018 in Review

Parallax Volatility Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2018, closing a stake of 1,001 shares — an estimated $53K sold.

Parallax Volatility Advisers first reported a position in EGRX in Q1 2016 and held it in 5 quarters. The position peaked at $1.74M in Q2 2016. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

  • Parallax Volatility Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,001 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $53K.
  • Parallax Volatility Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 5 quarters.
  • Parallax Volatility Advisers's Eagle Pharmaceuticals, Inc. position peaked at $1.74M in Q2 2016.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on Parallax Volatility Advisers's 13F filing for Q2 2018, filed 14 Aug 2018.